We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-15.65%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$215M
AUM Growth
-$26.2M
Cap. Flow
+$19.8M
Cap. Flow %
9.2%
Top 10 Hldgs %
74.42%
Holding
31
New
3
Increased
13
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
AFMD
Affimed
AFMD
+$10.8M
2
AMRN
Amarin Corp
AMRN
+$8.5M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$7.86M
4
RZLT icon
Rezolute
RZLT
+$7.49M
5
CSTL icon
Castle Biosciences
CSTL
+$6.86M

Top Sells

Rank Stock Value
1
ATRS
Antares Pharma, Inc.
ATRS
+$12.8M
2
ENTA icon
Enanta Pharmaceuticals
ENTA
+$8.54M
3
EOLS icon
Evolus
EOLS
+$6.58M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$5.14M
5
SRGA
Surgalign Holdings, Inc. Common Stock
SRGA
+$2.24M

Sector Composition

Rank Sector Weight
1 Healthcare 95.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELC icon
26
Celcuity
CELC
$4.01B
– –
-239,433
Closed -$2.24M
ENTA icon
27
Enanta Pharmaceuticals
ENTA
$370M
– –
-119,972
Closed -$8.54M
EOLS icon
28
Evolus
EOLS
$407M
– –
-586,224
Closed -$6.58M
NMTC icon
29
NeuroOne Medical Technologies
NMTC
$15.3M
– –
-41,351
Closed -$273K
ATRS
30
DELISTED
Antares Pharma, Inc.
ATRS
– –
-3,130,192
Closed -$12.8M
SRGA
31
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
– –
-245,856
Closed -$2.24M
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Stonepine Capital Management held 31 positions worth $215M, down 11% from $241M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Stonepine Capital Management deployed $19.8M of net new capital in Q2 2022, opening 3 new positions and adding to 13 existing holdings. Its largest new stake was Affimed: 314,377 shares worth $8.71M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was CTI BioPharma Corp. (DE) Common Stock, an estimated $5.14M trimmed.

  • Stonepine Capital Management's largest Q2 2022 buy was Affimed: 314,377 shares worth $8.71M.
  • Stonepine Capital Management added most to Amarin Corp in Q2 2022, an estimated $8.5M increase.
  • Stonepine Capital Management's biggest Q2 2022 reduction was CTI BioPharma Corp. (DE) Common Stock, cutting an estimated $5.14M.
  • Stonepine Capital Management fully exited Antares Pharma, Inc. in Q2 2022, selling an estimated $12.8M.
  • Stonepine Capital Management's ten largest holdings make up 74% of its $215M portfolio in Q2 2022.
  • Stonepine Capital Management opened 3 new positions and closed 6 in Q2 2022.
  • Stonepine Capital Management's portfolio value fell 11% quarter-over-quarter to $215M.

Based on Stonepine Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.